Analyst Ratings for Biogen
Portfolio Pulse from Benzinga Insights
In the last quarter, Biogen (NASDAQ:BIIB) received 24 analyst ratings, with 21 being bullish or somewhat bullish, and 3 indifferent. The average 12-month price target for the company is $333.33, a 2.26% decrease from the previous average of $341.05.
October 11, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen received mostly bullish analyst ratings in the last quarter. However, the average 12-month price target has decreased by 2.26%.
The majority of analyst ratings for Biogen are bullish, indicating a positive outlook for the company. However, the decrease in the average 12-month price target suggests some caution, which could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100